EPA and DHA consumption significantly benefits metabolic syndrome and type 11 diabetes

Metabolic syndrome, the precursor to type 11 diabetes, is characterised by dyslipidemia (including elevated total cholesterol and LDL-c), oxidation, inflammation, hypertension, glucose intolerance and obesity (especially abdominal obesity). This mini-review looked at the evidence for a role of omega-3 fatty acids in improving this profile and thus reducing the risk of the development of type 11 diabetes and cardiovascular disease among these patients; it was concluded that EPA and DHA consumption significantly benefits metabolic syndrome and type 2 diabetes primarily by favourable effects on elevated blood lipids and platelet aggregation. It was also noted that there is evidence that EPA and/or DHA consumption reduces conversion of metabolic syndrome to type 2 diabetes and reduces death rates from these conditions.

 

Click here to read the abstract.

 

Favourable effects of omega-3 PUFAs on a model of dyslipidemia, insulin resistance and obesity

This study examined the effectiveness of fish oil in reversing or improving dyslipidemia, insulin resistance (tissues do not respond to insulin) and obesity induced in rats by long-term feeding of a sucrose-rich diet. The fish oil reversed dyslipidemia and improved insulin action in the rats, it reduced the size of adipose (fat) cells which thus became more insulin sensitive and released less fatty acids into the blood stream. In muscle, the fish oil was found to normalize pathways of glucose metabolism. The authors concluded: “these effects could contribute to the normalization of glucose-stimulated insulin secretion and muscle insulin insensitivity”.

 

Click here to read the abstract

 

Omega-3 improves cardiovascular risk profile of type 11 diabetes

A systematic review was conducted, collating published evidence on the effects of omega-3 on patients with diabetes.  Twelve studies were examined, the results revealed a significant of omega-3 fats on two outcomes: reducing the level of diastolic blood pressure by a mean of 1.8 mm Hg and increasing factor VII (a blood clotting factor) by 24.9%, an addition to the recognised effects of omega-3 on blood lipids.

 

Click here to read the abstract       

 

EPA is beneficial in the early stages of diabetic nephropathy in a mouse model of type 11 diabetes

This study examined the effects of EPA on the early stage of type 2 diabetic nephropathy (a progressive kidney disease) in KKA(y)/Ta mice.  The mice were divided into two groups, the treatment group was injected with EPA ethyl ester at 1 g/kg per day from 12 to 20 weeks of age and the control group was injected with saline. EPA decreased the levels of urinary albumin (urinary protein) and serum triglycerides, and improved glucose intolerance in the mice. Tubulointerstitial fibrosis, characterized by accumulation of extracellular matrix proteins (part of animal tissue that usually provides structural support to cells), a hallmark of renal disease, was significantly decreased. Levels of malondialdehyde (a end product of fat oxidation by free radicals) were reduced, indicating a reduction in oxidative stress; a number of markers of inflammation and tissue repair were also down regulated, in particular the cytokine TGF beta-1. The authors speculated that the “effect might be mediated by attenuation of metabolic abnormalities and inhibition of renal inflammation, oxidative stress, and TGF-beta expression”. 

 

Click here to view the abstract.

EPA and DHA consumption significantly benefits metabolic syndrome and type 11 diabetes

Metabolic syndrome, the precursor to type 11 diabetes, is characterised by dyslipidemia (including elevated total cholesterol and LDL-c), oxidation, inflammation, hypertension, glucose intolerance and obesity (especially abdominal obesity). This mini-review looked at the evidence for a role of omega-3 fatty acids in improving this profile and thus reducing the risk of the development of type 11 diabetes and cardiovascular disease among these patients; it was concluded that EPA and DHA consumption significantly benefits metabolic syndrome and type 2 diabetes primarily by favourable effects on elevated blood lipids and platelet aggregation. It was also noted that there is evidence that EPA and/or DHA consumption reduces conversion of metabolic syndrome to type 2 diabetes and reduces death rates from these conditions.

 

Click here to read the abstract.

 

Favourable effects of omega-3 PUFAs on a model of dyslipidemia, insulin resistance and obesity

This study examined the effectiveness of fish oil in reversing or improving dyslipidemia, insulin resistance (tissues do not respond to insulin) and obesity induced in rats by long-term feeding of a sucrose-rich diet. The fish oil reversed dyslipidemia and improved insulin action in the rats, it reduced the size of adipose (fat) cells which thus became more insulin sensitive and released less fatty acids into the blood stream. In muscle, the fish oil was found to normalize pathways of glucose metabolism. The authors concluded: “these effects could contribute to the normalization of glucose-stimulated insulin secretion and muscle insulin insensitivity”.

 

Click here to read the abstract

 

Omega-3 improves cardiovascular risk profile of type 11 diabetes

A systematic review was conducted, collating published evidence on the effects of omega-3 on patients with diabetes.  Twelve studies were examined, the results revealed a significant of omega-3 fats on two outcomes: reducing the level of diastolic blood pressure by a mean of 1.8 mm Hg and increasing factor VII (a blood clotting factor) by 24.9%, an addition to the recognised effects of omega-3 on blood lipids.

 

Click here to read the abstract       

 

EPA is beneficial in the early stages of diabetic nephropathy in a mouse model of type 11 diabetes

This study examined the effects of EPA on the early stage of type 2 diabetic nephropathy (a progressive kidney disease) in KKA(y)/Ta mice.  The mice were divided into two groups, the treatment group was injected with EPA ethyl ester at 1 g/kg per day from 12 to 20 weeks of age and the control group was injected with saline. EPA decreased the levels of urinary albumin (urinary protein) and serum triglycerides, and improved glucose intolerance in the mice. Tubulointerstitial fibrosis, characterized by accumulation of extracellular matrix proteins (part of animal tissue that usually provides structural support to cells), a hallmark of renal disease, was significantly decreased. Levels of malondialdehyde (a end product of fat oxidation by free radicals) were reduced, indicating a reduction in oxidative stress; a number of markers of inflammation and tissue repair were also down regulated, in particular the cytokine TGF beta-1. The authors speculated that the “effect might be mediated by attenuation of metabolic abnormalities and inhibition of renal inflammation, oxidative stress, and TGF-beta expression”. 

 

Click here to view the abstract.